Tokudome N - Search Results

1

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.

Matsubara J, Mukai K, Kondo T, Yoshioka M, Kage H, Oda K, Kudo R, Ikeda S, Ebi H, Muro K, Hayashi R, Tokudome N, Yamamoto N, Muto M. Matsubara J, et al. Among authors: tokudome n. JAMA Netw Open. 2023 Jul 3;6(7):e2323336. doi: 10.1001/jamanetworkopen.2023.23336. JAMA Netw Open. 2023. PMID: 37459099 Free PMC article.

2

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.

Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, Hayes DF. Paoletti C, et al. Among authors: tokudome n. Clin Cancer Res. 2015 Jun 1;21(11):2487-98. doi: 10.1158/1078-0432.CCR-14-1913. Epub 2014 Nov 7. Clin Cancer Res. 2015. PMID: 25381338 Free PMC article.

3

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, Wong HY, Toro PV, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons HA, Dalton WB, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan AM, Schott A, Robinson D, Jacks KS, Lauring J, Hurley PJ, Hayes DF, Rae JM, Park BH. Chu D, et al. Among authors: tokudome n. Clin Cancer Res. 2016 Feb 15;22(4):993-9. doi: 10.1158/1078-0432.CCR-15-0943. Epub 2015 Aug 10. Clin Cancer Res. 2016. PMID: 26261103 Free PMC article.

4

Applicability of the Japanese equation for estimating glomerular filtration rate in patients with advanced-stage thoracic cancer.

Kikuchi T, Akamatsu H, Mori K, Tanaka A, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Nakanishi M, Ueda H, Yamamoto N. Kikuchi T, et al. Among authors: tokudome n. Respir Investig. 2016 Nov;54(6):479-483. doi: 10.1016/j.resinv.2016.05.007. Epub 2016 Jul 16. Respir Investig. 2016. PMID: 27886861

5

Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients.

Yagi S, Koh Y, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Endo K, Nakamura S, Higuchi M, Kanbara H, Nakanishi M, Ueda H, Yamamoto N. Yagi S, et al. Among authors: tokudome n. PLoS One. 2017 Jun 22;12(6):e0179744. doi: 10.1371/journal.pone.0179744. eCollection 2017. PLoS One. 2017. PMID: 28640869 Free PMC article.

6

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.

Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N. Sato K, et al. Among authors: tokudome n. Lung Cancer. 2018 Jan;115:71-74. doi: 10.1016/j.lungcan.2017.11.019. Epub 2017 Nov 21. Lung Cancer. 2018. PMID: 29290265 Free article.

7

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.

Tokudome N, Koh Y, Akamatsu H, Fujimoto D, Okamoto I, Nakagawa K, Hida T, Imamura F, Morita S, Yamamoto N. Tokudome N, et al. BMC Cancer. 2020 Feb 6;20(1):103. doi: 10.1186/s12885-020-6593-1. BMC Cancer. 2020. PMID: 32028909 Free PMC article.

8

Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, Tanaka M, Harutani Y, Yamagata N, Okuda Y, Furuta K, Sugimoto T, Teraoka S, Hayata A, Tokudome N, Ozawa Y, Mori K, Koh Y, Yamamoto N. Akamatsu H, et al. Among authors: tokudome n. Oncologist. 2020 Apr;25(4):e679-e683. doi: 10.1634/theoncologist.2019-0299. Epub 2019 Nov 19. Oncologist. 2020. PMID: 32297443 Free PMC article.

9

CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.

Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, Hayata A, Sugimoto T, Tanaka M, Takakura T, Furuta K, Okuda Y, Sato K, Teraoka S, Ueda H, Tokudome N, Kitamura Y, Fukuoka J, Nakanishi M, Koh Y, Yamamoto N. Ozawa Y, et al. Among authors: tokudome n. Cancer Sci. 2021 Jan;112(1):72-80. doi: 10.1111/cas.14705. Epub 2020 Nov 27. Cancer Sci. 2021. PMID: 33084148 Free PMC article.

10

Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.

Oyanagi J, Koh Y, Sato K, Teraoka S, Tokudome N, Hayata A, Akamatsu H, Ozawa Y, Nakanishi M, Ueda H, Yamamoto N. Oyanagi J, et al. Among authors: tokudome n. Clin Lung Cancer. 2021 Nov;22(6):e833-e841. doi: 10.1016/j.cllc.2021.04.007. Epub 2021 Apr 27. Clin Lung Cancer. 2021. PMID: 34049821 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters